These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 8512458)

  • 1. Long-term administration of probucol and QTc interval prolongation.
    Sasaki N; Saku K; Moroe K; Zhang B; Hirata K; Liu R; Arakawa K
    Artery; 1993; 20(2):115-21. PubMed ID: 8512458
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factors related to QT interval prolongation during probucol treatment.
    Ohya Y; Kumamoto K; Abe I; Tsubota Y; Fujishima M
    Eur J Clin Pharmacol; 1993; 45(1):47-52. PubMed ID: 8405029
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The long-term effects of probucol on serum lipid levels.
    McCaughan D
    Arch Intern Med; 1981 Oct; 141(11):1428-32. PubMed ID: 7025778
    [TBL] [Abstract][Full Text] [Related]  

  • 4. QTc-interval prolongation associated with slow intravenous erythromycin lactobionate infusions in critically ill patients: a prospective evaluation and review of the literature.
    Tschida SJ; Guay DR; Straka RJ; Hoey LL; Johanning R; Vance-Bryan K
    Pharmacotherapy; 1996; 16(4):663-74. PubMed ID: 8840374
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Influence of low high-density lipoprotein cholesterolemia induced by probucol on the progression of coronary atherosclerosis].
    Takahashi T; Hiasa Y; Harada S; Hosokawa S; Kato S; Tanimoto M; Kishi K; Ohtani R
    J Cardiol; 1997 Aug; 30(2):67-72. PubMed ID: 9300286
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of probucol on QT/QS2 relation and systolic time intervals.
    Romics L; Littmann L; László Z; Fenyvesi T
    Int J Cardiol; 1988 Jun; 19(3):303-8. PubMed ID: 3397194
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Plasma levels of probucol in man after single and repeated oral doses (author's transl)].
    Heeg JF; Tachizawa H
    Nouv Presse Med; 1980 Oct; 9(40):2990-4. PubMed ID: 7443437
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [A comparison of the hypolipidemic action of probucol at doses of 500 and 1000 mg/day in moderate hyperlipoproteinemia].
    Tvorogova MG; Lupanov VP; Nuraliev EIu; Zaĭtseva TM; Kukharchuk VV; Titov VN
    Ter Arkh; 1998; 70(8):17-21. PubMed ID: 9770737
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lack of effect of aprepitant or its prodrug fosaprepitant on QTc intervals in healthy subjects.
    Marbury TC; Jin B; Panebianco D; Murphy MG; Sun H; Evans JK; Han TH; Constanzer ML; Dru J; Shadle CR
    Anesth Analg; 2009 Aug; 109(2):418-25. PubMed ID: 19608812
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loratadine and terfenadine interaction with nefazodone: Both antihistamines are associated with QTc prolongation.
    Abernethy DR; Barbey JT; Franc J; Brown KS; Feirrera I; Ford N; Salazar DE
    Clin Pharmacol Ther; 2001 Mar; 69(3):96-103. PubMed ID: 11240972
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Probucol-induced QT prolongation and syncope.
    Tamura M; Ueki Y; Ohtsuka E; Oribe M; Seita M; Oribe K; Ito M
    Jpn Circ J; 1994 May; 58(5):374-7. PubMed ID: 8022053
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Frequency and prognostic significance of QT prolongation in chronic renal failure patients.
    Voiculescu M; Ionescu C; Ismail G
    Rom J Intern Med; 2006; 44(4):407-17. PubMed ID: 18386617
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Prolonged probucol treatment in patients with cardiovascular diseases (author's transl)].
    Scebat L; Renais J
    Nouv Presse Med; 1980 Oct; 9(40):3008-10. PubMed ID: 7443441
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation between QTc interval and clinical severity of subarachnoid hemorrhage depends on the QTc formula used.
    Colkesen AY; Sen O; Giray S; Acil T; Ozin B; Muderrisoglu H
    Pacing Clin Electrophysiol; 2007 Dec; 30(12):1482-6. PubMed ID: 18070302
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of treatment with somatostatin analogues on QT interval duration in acromegalic patients.
    Fatti LM; Scacchi M; Lavezzi E; Pecori Giraldi F; De Martin M; Toja P; Michailidis G; Stramba-Badiale M; Cavagnini F
    Clin Endocrinol (Oxf); 2006 Nov; 65(5):626-30. PubMed ID: 17054464
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lipid-lowering effects of colesevelam HCl in combination with ezetimibe.
    Bays H; Rhyne J; Abby S; Lai YL; Jones M
    Curr Med Res Opin; 2006 Nov; 22(11):2191-200. PubMed ID: 17076980
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacist monitoring of QTc interval-prolonging medications in critically ill medical patients: a pilot study.
    Ng TM; Bell AM; Hong C; Hara JM; Touchette DR; Danskey KN; Lindsay TT; Puumala SE
    Ann Pharmacother; 2008 Apr; 42(4):475-82. PubMed ID: 18319393
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of probucol on HDL metabolism and class B type I scavenger receptor (SR-BI) expression in the liver of hypercholesterolemic rabbits.
    Hong SC; Zhao SP; Wu ZH
    Int J Cardiol; 2007 Jan; 115(1):29-35. PubMed ID: 16766063
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vascular endothelial growth factor serum concentrations in hypercholesterolemic patients.
    Trapé J; Morales C; Molina R; Filella X; Marcos JM; Salinas R; Franquesa J
    Scand J Clin Lab Invest; 2006; 66(3):261-7. PubMed ID: 16714254
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Retrospective analysis of electrocardiographic changes after administration of oral or intravenous garenoxacin in five phase I, placebo-controlled studies in healthy volunteers.
    Wang Z; Grasela DM; Krishna G
    Clin Ther; 2007 Jun; 29(6):1098-106. PubMed ID: 17692724
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.